X
<

What's Driving Pfizer’s Valuation after 2Q17 Earnings

PART:
1 2 3 4 5 6 7 8
What's Driving Pfizer’s Valuation after 2Q17 Earnings PART 1 OF 8

Pfizer’s Valuation after 2Q17 Earnings

A look at Pfizer’s valuation

Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16.

Pfizer’s Valuation after 2Q17 Earnings

Interested in PFE? Don't miss the next report.

Receive e-mail alerts for new research on PFE

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The company missed analysts’ estimates for revenues in 2Q17 and reported revenues of $12.89 billion, compared to estimates of $13.08 billion for 2Q17. Also, the company reported earnings per share of $0.67 for 2Q17, beating analysts’ estimates for EPS of $0.66 in 2Q17.

Forward PE

Pfizer was trading at a forward PE multiple of ~12.5x on August 10, as compared to the industry average of ~16.5x. Johnson & Johnson (JNJ), Eli Lilly and Co. (LLY), and Bristol-Myers Squibb (BMY) have forward PE multiples of 17.6x, 18.8x, and 18.4x, respectively.

Forward EV/EBITDA

On a capital structure–neutral basis, Pfizer currently trades at ~10.3x, which is much lower than the industry’s average of ~13.4x as of August 10. Johnson & Johnson (JNJ), Eli Lilly and Co. (LLY), and Bristol-Myers Squibb (BMY), have forward EV/EBITDA multiples of 13.3x, 13.9x, and 15.3x, respectively.

Analysts’ recommendations

Pfizer’s stock has fallen nearly 4.6% in the last 12 months while the stock price has risen ~3.0% in 2017 year-to-date. Analysts estimate the stock has a potential to return ~12.4%. Analysts’ recommendations show a 12-month targeted price of $37.60 per share, compared to the last price of $33.45 per share on August 9. Also, there are 21 analysts tracking Pfizer. Eleven recommend a “buy” while ten recommend a “hold.”

The consensus rating on Pfizer’s stock is 2.55, representing a “hold” for long-term investors and a moderate “buyæ for value investors. Changes in analysts’ estimates and recommendations are based on changing trends in the stock price.

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) invests 8.6% of its total assets in Pfizer (PFE). FTXH also invests 8.5% in Johnson & Johnson (JNJ), 4.3% in Bristol-Myers Squibb (BMY), and 4.2% in Eli Lilly and Co. (LLY).

X

Please select a profession that best describes you: